← back to search

Huijun Yang

Chongqing University of Posts and Telecommunications · CN
Area of research
Molecular Biology · Genetics
Research interest
Research interests include RNA modifications and cancer, Glioma Diagnosis and Treatment, Microtubule and mitosis dynamics, and Cancer Mechanisms and Therapy.
h-index
29
citations
3,622
works
127
NIH funding
primary concept
email

Recent publications

Clinical pathological characteristics correlation of H3F3A gene mutation in giant cell tumor of bone: a study of 96 cases
Translational Cancer Research 2025cited by 1position: middledoi
PCR20 Assessing Activity Limitations Caused by Rheumatoid Arthritis to Inform Appropriate Selection of Patient-Reported Outcomes Measures
Value in Health 2024cited by 0position: firstdoi
Acupuncture for neuropathic pain: A meta-analysis of randomized control trials
Frontiers in Neurology 2023cited by 15position: middledoi
Immune regulation and prognosis indicating ability of a newly constructed multi-genes containing signature in clear cell renal cell carcinoma
BMC Cancer 2023cited by 4position: middledoi
Exploring the treatment of <scp>COVID</scp>‐19 with Yinqiao powder based on network pharmacology
Phytotherapy Research 2021cited by 59position: middledoi
Dietary supplements and herbal medicine for COVID-19: A systematic review of randomized control trials
Clinical Nutrition ESPEN 2021cited by 44position: middledoi
[Retracted] Effects of Tai Chi on Patients with Mild Cognitive Impairment: A Systematic Review and Meta‐analysis of Randomized Controlled Trials
BioMed Research International 2021cited by 32position: middledoi
Epidemiological characteristics of dengue in mainland China from 1990 to 2019
Medicine 2020cited by 42position: middledoi
NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling
Nature 2019cited by 222position: middledoi
Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma
Cancer Cell 2016cited by 167position: middledoi
Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA
Science 2013cited by 684position: middledoi
De-Repression of <i>PDGFRβ</i> Transcription Promotes Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Glioblastoma Patients
Cancer Discovery 2013cited by 142position: middledoi
A Kinome-Wide RNAi Screen in Drosophila Glia Reveals That the RIO Kinases Mediate Cell Proliferation and Survival through TORC2-Akt Signaling in Glioblastoma
PLoS Genetics 2013cited by 133position: middledoi
PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies
Proceedings of the National Academy of Sciences 2013cited by 64position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Paul S. Mischel · Stanford Health Care6 papers (2013–2019)Webster K. Cavenee · University of California San Diego5 papers (2013–2016)Frank B. Furnari · University of California San Diego4 papers (2013–2019)C. David James · Northwestern University3 papers (2013–2016)Zitong Feng · Guangzhou University of Chinese Medicine3 papers (2021–2023)Timothy F. Cloughesy · UCLA Medical Center3 papers (2013–2016)Beatrice Gini · University of California, San Francisco3 papers (2013–2016)Shaoyang Cui · Guangzhou University of Chinese Medicine3 papers (2021–2023)Ningning Shen · Xuzhou Medical College2 papers (2023–2025)Wenxia Ma · University of Alabama at Birmingham2 papers (2023–2025)German G. Gomez · Institut de Recherche sur le Cancer et le Vieillissement de Nice2 papers (2013–2013) · 2 papers (2021–2021)David A. Nathanson · La Jolla Bioengineering Institute2 papers (2013–2013)Xuzhi Wang · Tianjin Normal University2 papers (2023–2025)Tomoyuki Koga · Hosei University2 papers (2013–2019)Tomoo Matsutani · Chiba University2 papers (2013–2016)Manisha Salinas · Drexel University2 papers (2021–2021)Ivan Babić · BioMarin (United States)2 papers (2013–2013)Jill Wykosky · Takeda (United States)2 papers (2013–2013)Kiwook Hwang · California Institute of Technology2 papers (2013–2016)